Acute myeloid leukemia (AML) is thought to be the consequence of two broad complementation classes of mutations: those that confer a proliferative and/or survival advantage to hematopoietic progenitors, and those that impair hematopoietic differentiation and confer properties of self-renewal. 1 AML in Down syndrome (DS) children shows unique characteristics of the predominance of acute megakaryoblastic leukemia (AMKL) and a preceding history of transient myeloproliferative disorder (TMD), whose blasts are morphologically and phenotypically indistinguishable from those of AMKL. TMD develops in about 10% of DS infants and resolves spontaneously in most cases, while 20% of TMD cases develop AMKL within 3 years. Somatic mutations of the GATA1 gene are reportedly associated with AMKL in DS children. 2 In addition, subsequent reports demonstrated that GATA1 mutations are an early event in DS leukemogenesis and contribute to the pathogenesis of both TMD and AMKL, suggesting that the acquisition of additional genetic alterations might be necessary for progression from TMD to AMKL; 3 however, it remains unclear which mutations are involved in the progression of TMD to AMKL. Furthermore, little is known about which genetic alterations are involved in the pathogenesis of non-DS AMKL. Recently, Walters et al. 4 reported activating mutations of the JAK3 gene in each of 16 non-DS and three DS AMKL patients as well as an AMKL cell line CMK derived from a DS AMKL patient. These mutations consisted of A572V and V722I substitutions in the JH2 pseudokinase domain, and a P132T substitution in the JH6 domain of the receptor-binding domain. Although the mutated positions were different, all mutated JAK3 products were constitutively activated and conferred autonomous proliferation of Ba/F3 cells. These results suggested that activating JAK3 mutations involved in the pathogenesis of AMKL both with and without DS, whereas it remains unclear how JAK3 mutations cooperate with other genetic alterations during leukemogenesis. In this study, we analyzed JAK3 mutations in non-DS adults with AMKL and DS children with AMKL or TMD in comparison with mutations in GATA1, p53, FLT3 and N-RAS genes.
The study population included eight non-DS adults with AMKL, and 11 AMKL and two TMD children with DS. The diagnosis of AMKL and TMD was based on morphology, histopathology, the expression of leukocyte differentiation antigens and/or the French-American-British (FAB) classification. The diagnosis of DS was confirmed by conventional cytogenetic analysis. Bone marrow (BM) samples were obtained from patients with AMKL and TMD at diagnosis after obtaining informed consent for banking and molecular analyses from all adult patients or parents of children. High-molecular-weight DNA was extracted from the samples by the standard method. For screening of JAK3 mutations, we amplified genomic DNA corresponding to all 23 exons of the JAK3 gene by polymerase JAK3 mutations were found in three patients. In DS-M7-2, two distinct JAK3 mutations were found in the same allele. GATA1 mutations were found in all AMKL and TMD patients with DS, but not in adult non-DS AMKL patients.
Letters to the Editor chain reaction (PCR) using 19 primer pairs. Amplified products were subjected to denaturing HPLC (DHPLC) analysis using the WAVE Maker System (Transgenomic Inc., San Jose, CA, USA). DHPLC gradients and temperatures were determined using WAVE Maker System software. When heterozygous profiles were identified by visual inspection of the chromatograms, amplified products were cloned into pGEM-T Easy vector (Promega, Madison, WI, USA) and sequenced on a DNA sequencer (310; Applied Biosystems, Foster City, CA, USA) using a BigDye terminator cycle-sequencing kit (Applied Biosystems). GATA1 mutations of exon 2, FLT3 mutations, N-RAS mutations of codons 12, 13 and 61 and p53 mutations of exons 5-8 were examined as previously reported. 5, 6 Mutations of JAK3 were found in each adult with non-DS AMKL, DS AMKL and DS TMD; a M576L substitution in the JH2 pseudokinase domain in adult non-DS AMKL (UPN: adult M7-8); A573V and A593T substitutions in DS AMKL (UPN: DS-M7-2) and an I87T substitution in the JH7 domain of the receptor-binding domain in DS TMD (UPN: DS-TMD-2) (Figure 1 ). In the DS-M7-2 patient, A573V and A593T substitutions were found in the same allele. We therefore sequenced 20 independent clones to examine for the existence of single mutant alleles, and all mutant alleles had both mutations, indicating that most leukemia cells had both mutations at diagnosis. GATA1 mutations were observed in all DS AMKL and DS TMD patients, but not in non-DS AMKL adults. p53 Mutations were found in three of eight non-DS AMKL and two of eleven DS AMKL patients, but not in two TMD patients. No FLT3 and N-RAS mutations were found in any AMKL and TMD patients (Table 1) .
In this study, we found four types of JAK3 mutations in AMKL and TMD patients. These mutations were different from those previously found in AMKL patients and the megakaryoblastic cell line CMK, while it was notable that all JAK3 mutations uniformly occurred in the pseudokinase domain or receptorbinding domain. JAK3 consists of seven Janus homology (JH) domains, JH1-JH7. The JH2 pseudokinase domain lies adjacent to the JH1 C-terminal kinase domain. Although the pseudokinase domain itself lacks catalytic activity, it has been demonstrated that a number of mutations in this domain derived from severe combined immunodeficiency (SCID) patients abrogate kinase activity indicating its essential regulatory activity for the kinase domain. 7 Therefore, it is an important question why JAK3 mutations identified in AMKL are activating mutations in contrast to loss-of-function mutations identified in SCID patients. Walters et al. 4 speculated the possible autoinhibitory function of the pseudokinase domain against the kinase domain by structural modeling analysis. Since the activating mutation in the JH2 pseudokinase domain of JAK2 (JAK2 V617F ) was preferentially found in myeloproliferative disorders, 8 JAK3 mutations in this region might be involved in the proliferation mechanism of megakaryoblastic cells. However, in contrast to the JAK2 mutation, mutations of JAK3 were observed in a variety of residues within the JH2 pseudokinase domain. Further analysis is therefore necessary to examine whether each JAK3 mutation identified in this study is an activating mutation. The important aspect of this study was the JAK3 mutation in TMD patients. This I87T mutation was found in the JH7 domain of the receptor-binding domain. N-terminal JH5-JH7 domains of JAK3, which has homology to the band four-point-one, ezrin, radixin, moesin (FERM) domain-containing proteins, mediates binding to the common g-subunit (g c ), which is a common receptor subunit for IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 cytokines. 7 Since mutations in this domain identified in SCID patients are also demonstrated to abrogate the binding capacity to g c and catalytic activity, it is necessary to examine whether the I87T mutation is an activating mutation like the P132T mutation found in non-DS AMKL patients. The fact that the JAK3 mutation was found in a TMD patient indicated that it is an early event during the development of AMKL in DS patients, whereas its pathological significance should be carefully examined. Furthermore, since we could not find any relationship between the JAK3 mutation and GATA1, p53, FLT3 and N-RAS mutations, it should be further examined which genetic alterations collaborate with JAK3 mutations, and how JAK3 mutations are involved in the development and/or progression of AMKL.
